Cancer pharmacoinformatics: Databases and analytical tools.
Cancer Databases
Drug Discovery
Genomics
Immunology
Metabolomics
Pharmacoinformatics
Journal
Functional & integrative genomics
ISSN: 1438-7948
Titre abrégé: Funct Integr Genomics
Pays: Germany
ID NLM: 100939343
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
29
07
2024
accepted:
03
09
2024
revised:
26
08
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
18
9
2024
Statut:
epublish
Résumé
Cancer is a subject of extensive investigation, and the utilization of omics technology has resulted in the generation of substantial volumes of big data in cancer research. Numerous databases are being developed to manage and organize this data effectively. These databases encompass various domains such as genomics, transcriptomics, proteomics, metabolomics, immunology, and drug discovery. The application of computational tools into various core components of pharmaceutical sciences constitutes "Pharmacoinformatics", an emerging paradigm in rational drug discovery. The three major features of pharmacoinformatics include (i) Structure modelling of putative drugs and targets, (ii) Compilation of databases and analysis using statistical approaches, and (iii) Employing artificial intelligence/machine learning algorithms for the discovery of novel therapeutic molecules. The development, updating, and analysis of databases using statistical approaches play a pivotal role in pharmacoinformatics. Multiple software tools are associated with oncoinformatics research. This review catalogs the databases and computational tools related to cancer drug discovery and highlights their potential implications in the pharmacoinformatics of cancer.
Identifiants
pubmed: 39294509
doi: 10.1007/s10142-024-01445-5
pii: 10.1007/s10142-024-01445-5
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
166Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Abbott M, Ustoyev Y (2019) Cancer and the Immune System: The History and Background of Immunotherapy. Semin Oncol Nurs 35:150923. https://doi.org/10.1016/j.soncn.2019.08.002
doi: 10.1016/j.soncn.2019.08.002
pubmed: 31526550
Adam G, Rampasek L, Safikhani Z et al (2020) Machine learning approaches to drug response prediction: challenges and recent progress. NPJ Precis Oncol 4:19. https://doi.org/10.1038/s41698-020-0122-1
doi: 10.1038/s41698-020-0122-1
pubmed: 32566759
pmcid: 7296033
Aguero F, Al-Lazikani B, Aslett M et al (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7:900–907. https://doi.org/10.1038/nrd2684
doi: 10.1038/nrd2684
pubmed: 18927591
pmcid: 3184002
Ahmadi Moughari F, Eslahchi C (2020) ADRML: anticancer drug response prediction using manifold learning. Sci Rep 10:14245. https://doi.org/10.1038/s41598-020-71257-7
doi: 10.1038/s41598-020-71257-7
pubmed: 32859983
pmcid: 7456328
Aksoy BA, Dancik V, Smith K, et al. (2017) CTD2 Dashboard: a searchable web interface to connect validated results from the Cancer Target Discovery and Development Network. Database (Oxford) 2017. https://doi.org/10.1093/database/bax054
Amar D, Izraeli S, Shamir R (2017) Utilizing somatic mutation data from numerous studies for cancer research: proof of concept and applications. Oncogene 36:3375–3383. https://doi.org/10.1038/onc.2016.489
doi: 10.1038/onc.2016.489
pubmed: 28092680
pmcid: 5485176
Ashok G, Ramaiah S (2022) A critical review of datasets and computational suites for improving cancer theranostics and biomarker discovery. Med Oncol 39:206. https://doi.org/10.1007/s12032-022-01815-8
doi: 10.1007/s12032-022-01815-8
pubmed: 36175717
Aslam B, Basit M, Nisar MA et al (2017) Proteomics: Technologies and Their Applications. J Chromatogr Sci 55:182–196. https://doi.org/10.1093/chromsci/bmw167
doi: 10.1093/chromsci/bmw167
pubmed: 28087761
Bairoch A, Apweiler R, Wu CH et al (2005) The Universal Protein Resource (UniProt). Nucleic Acids Res 33:D154-159. https://doi.org/10.1093/nar/gki070
doi: 10.1093/nar/gki070
pubmed: 15608167
Bamford S, Dawson E, Forbes S et al (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91:355–358. https://doi.org/10.1038/sj.bjc.6601894
doi: 10.1038/sj.bjc.6601894
pubmed: 15188009
pmcid: 2409828
Baptista D, Ferreira PG, Rocha M (2021) Deep learning for drug response prediction in cancer. Brief Bioinform 22:360–379. https://doi.org/10.1093/bib/bbz171
doi: 10.1093/bib/bbz171
pubmed: 31950132
Barbarino JM, Whirl-Carrillo M, Altman RB et al (2018) PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med 10:e1417. https://doi.org/10.1002/wsbm.1417
doi: 10.1002/wsbm.1417
pubmed: 29474005
pmcid: 6002921
Barras D, Widmann C (2011) Promises of apoptosis-inducing peptides in cancer therapeutics. Curr Pharm Biotechnol 12:1153–1165. https://doi.org/10.2174/138920111796117337
doi: 10.2174/138920111796117337
pubmed: 21470140
Barretina J, Caponigro G, Stransky N et al (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603–607. https://doi.org/10.1038/nature11003
doi: 10.1038/nature11003
pubmed: 22460905
pmcid: 3320027
Barrett T, Wilhite SE, Ledoux P et al (2013) NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res 41:D991-995. https://doi.org/10.1093/nar/gks1193
doi: 10.1093/nar/gks1193
pubmed: 23193258
Basu A, Bodycombe NE, Cheah JH et al (2013) An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154:1151–1161. https://doi.org/10.1016/j.cell.2013.08.003
doi: 10.1016/j.cell.2013.08.003
pubmed: 23993102
pmcid: 3954635
Bausch-Fluck D, Hofmann A, Bock T et al (2015) A mass spectrometric-derived cell surface protein atlas. PLoS ONE 10:e0121314. https://doi.org/10.1371/journal.pone.0121314
doi: 10.1371/journal.pone.0121314
pubmed: 25894527
pmcid: 4404347
Beger RD (2013) A review of applications of metabolomics in cancer. Metabolites 3:552–574. https://doi.org/10.3390/metabo3030552
doi: 10.3390/metabo3030552
pubmed: 24958139
pmcid: 3901293
Berger AH, Brooks AN, Wu X et al (2016) High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell 30:214–228. https://doi.org/10.1016/j.ccell.2016.06.022
doi: 10.1016/j.ccell.2016.06.022
pubmed: 27478040
pmcid: 5003022
Bharatam PV (2021) Computer-Aided Drug Design. In: Poduri R (ed) Drug Discovery and Development. Springer Singapore Singapore, pp. 137–210
Bharatam PV, Khanna S, Francis SM (2008) Modeling and Informatics in Drug DesignPreclinical Development Handbook. pp. 1–45
Blekherman G, Laubenbacher R, Cortes DF et al (2011) Bioinformatics tools for cancer metabolomics. Metabolomics 7:329–343. https://doi.org/10.1007/s11306-010-0270-3
doi: 10.1007/s11306-010-0270-3
pubmed: 21949492
pmcid: 3155682
Borgan E, Sitter B, Lingjaerde OC et al (2010) Merging transcriptomics and metabolomics–advances in breast cancer profiling. BMC Cancer 10:628. https://doi.org/10.1186/1471-2407-10-628
doi: 10.1186/1471-2407-10-628
pubmed: 21080935
pmcid: 2996395
Bojorquez DCQ, Campos MRS (2023) Traditional and Novel Computer-Aided Drug Design (CADD) Approaches in the Anticancer Drug Discovery Process. Curr Cancer Drug Targets 23:333–345. https://doi.org/10.2174/1568009622666220705104249
doi: 10.2174/1568009622666220705104249
Brum AM, van de Peppel J, van der Leije CS et al (2015) Connectivity Map-based discovery of parbendazole reveals targetable human osteogenic pathway. Proc Natl Acad Sci USA 112:12711–12716. https://doi.org/10.1073/pnas.1501597112
doi: 10.1073/pnas.1501597112
pubmed: 26420877
pmcid: 4611615
Bruno AE, Li L, Kalabus JL et al (2012) miRdSNP: a database of disease-associated SNPs and microRNA target sites on 3’UTRs of human genes. BMC Genomics 13:44. https://doi.org/10.1186/1471-2164-13-44
doi: 10.1186/1471-2164-13-44
pubmed: 22276777
pmcid: 3287127
Bulusu KC, Tym JE, Coker EA et al (2014) canSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Res 42:D1040-1047. https://doi.org/10.1093/nar/gkt1182
doi: 10.1093/nar/gkt1182
pubmed: 24304894
Burley SK (2000) An overview of structural genomics. Nat Struct Biol 7(Suppl):932–934. https://doi.org/10.1038/80697
doi: 10.1038/80697
pubmed: 11103991
can SAR.ai. https://cansar.ai/ . Cited 7 July 2023
Carles F, Bourg S, Meyer C, et al. (2018) PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials. Molecules 23. https://doi.org/10.3390/molecules23040908
Casaletto J, Maglic D, Toure BB et al (2021) Abstract 1455: RLY-4008, a novel precision therapy for FGFR2-driven cancers designed to potently and selectively inhibit FGFR2 and FGFR2 resistance mutations. Can Res 81:1455–1455. https://doi.org/10.1158/1538-7445.Am2021-1455
doi: 10.1158/1538-7445.Am2021-1455
Caspi R, Billington R, Fulcher CA et al (2018) The MetaCyc database of metabolic pathways and enzymes. Nucleic Acids Res 46:D633–D639. https://doi.org/10.1093/nar/gkx935
doi: 10.1093/nar/gkx935
pubmed: 29059334
Celebi R, Ot BDW, Movva R et al (2019) In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data. Sci Rep 9:8949. https://doi.org/10.1038/s41598-019-45236-6
doi: 10.1038/s41598-019-45236-6
pubmed: 31222109
pmcid: 6586895
Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095
doi: 10.1158/2159-8290.CD-12-0095
pubmed: 22588877
Chakravarty D, Gao J, Phillips SM et al. (2017) OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017. https://doi.org/10.1200/PO.17.00011
Chang Y, Park H, Yang HJ et al (2018) Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature. Sci Rep 8:8857. https://doi.org/10.1038/s41598-018-27214-6
doi: 10.1038/s41598-018-27214-6
pubmed: 29891981
pmcid: 5996063
Charoentong P, Angelova M, Efremova M et al (2012) Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother 61:1885–1903. https://doi.org/10.1007/s00262-012-1354-x
doi: 10.1007/s00262-012-1354-x
pubmed: 22986455
pmcid: 3493665
Chen C, Wang J, Pan D et al (2020) (2023) Applications of multi-omics analysis in human diseases. MedComm 4:e315. https://doi.org/10.1002/mco2.315
doi: 10.1002/mco2.315
Chen J, Cheong HH, Siu SWI (2021a) xDeep-AcPEP: Deep Learning Method for Anticancer Peptide Activity Prediction Based on Convolutional Neural Network and Multitask Learning. J Chem Inf Model 61:3789–3803. https://doi.org/10.1021/acs.jcim.1c00181
doi: 10.1021/acs.jcim.1c00181
pubmed: 34327990
Chen J, Liu X, Shen L et al. (2021) CMBD: a manually curated cancer metabolic biomarker knowledge database. Database (Oxford) 2021. https://doi.org/10.1093/database/baaa094
Chen X, Ji ZL, Chen YZ (2002) TTD: Therapeutic Target Database. Nucleic Acids Res 30:412–415. https://doi.org/10.1093/nar/30.1.412
doi: 10.1093/nar/30.1.412
pubmed: 11752352
pmcid: 99057
Chen X, Liu M, Gilson MK (2001) BindingDB: a web-accessible molecular recognition database. Comb Chem High Throughput Screen 4:719–725. https://doi.org/10.2174/1386207013330670
doi: 10.2174/1386207013330670
pubmed: 11812264
Cheng F, Lu W, Liu C et al (2019) A genome-wide positioning systems network algorithm for in silico drug repurposing. Nat Commun 10:3476. https://doi.org/10.1038/s41467-019-10744-6
doi: 10.1038/s41467-019-10744-6
pubmed: 31375661
pmcid: 6677722
Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17:297–303. https://doi.org/10.1038/nm.2323
doi: 10.1038/nm.2323
pubmed: 21383744
Chiu YC, Chen HH, Zhang T et al (2019) Predicting drug response of tumors from integrated genomic profiles by deep neural networks. BMC Med Genomics 12:18. https://doi.org/10.1186/s12920-018-0460-9
doi: 10.1186/s12920-018-0460-9
pubmed: 30704458
pmcid: 6357352
Chou PH, Liao WC, Tsai KW et al (2019) TACCO, a Database Connecting Transcriptome Alterations, Pathway Alterations and Clinical Outcomes in Cancers. Sci Rep 9:3877. https://doi.org/10.1038/s41598-019-40629-z
doi: 10.1038/s41598-019-40629-z
pubmed: 30846808
pmcid: 6405743
Clark K, Vendt B, Smith K et al (2013) The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 26:1045–1057. https://doi.org/10.1007/s10278-013-9622-7
doi: 10.1007/s10278-013-9622-7
pubmed: 23884657
pmcid: 3824915
Clifford JN, Hoie MH, Deleuran S et al. (2022) BepiPred-3.0: Improved B-cell epitope prediction using protein language models. Protein Sci 31:e4497. https://doi.org/10.1002/pro.4497
Clinical Proteomic Tumor Analysis Consortium (CPTAC). https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/clinical-proteomic-tumor-analysis-consortium-cptac . Cited 30 January 2024
Clough E, Barrett T (2016) The gene expression omnibus databaseStatistical genomics. Springer, pp. 93-110
Collins I, Workman P (2006) New approaches to molecular cancer therapeutics. Nat Chem Biol 2:689–700. https://doi.org/10.1038/nchembio840
doi: 10.1038/nchembio840
pubmed: 17108987
Consortium GT (2013) The Genotype-Tissue Expression (GTEx) project. Nat Genet 45:580–585. https://doi.org/10.1038/ng.2653
doi: 10.1038/ng.2653
Cortazar AR, Torrano V, Martin-Martin N et al (2018) CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets. Cancer Res 78:6320–6328. https://doi.org/10.1158/0008-5472.CAN-18-1669
doi: 10.1158/0008-5472.CAN-18-1669
pubmed: 30232219
Cui W, Aouidate A, Wang S et al (2020) Discovering Anti-Cancer Drugs via Computational Methods. Front Pharmacol 11:733. https://doi.org/10.3389/fphar.2020.00733
doi: 10.3389/fphar.2020.00733
pubmed: 32508653
pmcid: 7251168
Del Giacco L, Cattaneo C (2012) Introduction to genomics. Methods Mol Biol 823:79–88. https://doi.org/10.1007/978-1-60327-216-2_6
doi: 10.1007/978-1-60327-216-2_6
pubmed: 22081340
Delgado JL, Hsieh CM, Chan NL et al (2018) Topoisomerases as anticancer targets. Biochem J 475:373–398. https://doi.org/10.1042/BCJ20160583
doi: 10.1042/BCJ20160583
pubmed: 29363591
Deng X, Das S, Valdez K et al. (2019) SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment. Cancers (Basel) 11. https://doi.org/10.3390/cancers11111682
Dhusia K, Madrid C, Su Z et al (2022) EXCESP: A Structure-Based Online Database for Extracellular Interactome of Cell Surface Proteins in Humans. J Proteome Res 21:349–359. https://doi.org/10.1021/acs.jproteome.1c00612
doi: 10.1021/acs.jproteome.1c00612
pubmed: 34978816
di Micco P, Antolin AA, Mitsopoulos C et al (2023) canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Res 51:D1212–D1219. https://doi.org/10.1093/nar/gkac1004
doi: 10.1093/nar/gkac1004
pubmed: 36624665
Diaz-Gay M, Vila-Casadesus M, Franch-Exposito S et al (2018) Mutational Signatures in Cancer (MuSiCa): a web application to implement mutational signatures analysis in cancer samples. BMC Bioinformatics 19:224. https://doi.org/10.1186/s12859-018-2234-y
doi: 10.1186/s12859-018-2234-y
pubmed: 29898651
pmcid: 6001047
Dlamini Z, Francies FZ, Hull R et al (2020) Artificial intelligence (AI) and big data in cancer and precision oncology. Comput Struct Biotechnol J 18:2300–2311. https://doi.org/10.1016/j.csbj.2020.08.019
doi: 10.1016/j.csbj.2020.08.019
pubmed: 32994889
pmcid: 7490765
Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207–210. https://doi.org/10.1093/nar/30.1.207
doi: 10.1093/nar/30.1.207
pubmed: 11752295
pmcid: 99122
Edwards NJ, Oberti M, Thangudu RR et al (2015) The CPTAC Data Portal: A Resource for Cancer Proteomics Research. J Proteome Res 14:2707–2713. https://doi.org/10.1021/pr501254j
doi: 10.1021/pr501254j
pubmed: 25873244
Eisner R, Stretch C, Eastman T et al (2010) Learning to predict cancer-associated skeletal muscle wasting from 1H-NMR profiles of urinary metabolites. Metabolomics 7:25–34. https://doi.org/10.1007/s11306-010-0232-9
doi: 10.1007/s11306-010-0232-9
Fahy E, Sud M, Cotter D et al (2007) LIPID MAPS online tools for lipid research. Nucleic Acids Res 35:W606-612. https://doi.org/10.1093/nar/gkm324
doi: 10.1093/nar/gkm324
pubmed: 17584797
pmcid: 1933166
Feng F, Shen B, Mou X et al (2021) Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. J Genet Genomics 48:540–551. https://doi.org/10.1016/j.jgg.2021.03.007
doi: 10.1016/j.jgg.2021.03.007
pubmed: 34023295
Feng G, Yao H, Li C et al (2022) ME-ACP: Multi-view neural networks with ensemble model for identification of anticancer peptides. Comput Biol Med 145:105459. https://doi.org/10.1016/j.compbiomed.2022.105459
doi: 10.1016/j.compbiomed.2022.105459
pubmed: 35358753
Fenyö D (2010) Computational Biology. Springer
doi: 10.1007/978-1-60761-842-3
Ferlay J, Colombet M, Soerjomataram I, et al. (2021) Cancer statistics for the year 2020: An overview. Int J Cancer. https://doi.org/10.1002/ijc.33588
Freshour SL, Kiwala S, Cotto KC et al (2021) Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res 49:D1144–D1151. https://doi.org/10.1093/nar/gkaa1084
doi: 10.1093/nar/gkaa1084
pubmed: 33237278
Frolkis A, Knox C, Lim E et al (2010) SMPDB: The Small Molecule Pathway Database. Nucleic Acids Res 38:D480-487. https://doi.org/10.1093/nar/gkp1002
doi: 10.1093/nar/gkp1002
pubmed: 19948758
Gao J, Aksoy BA, Dogrusoz U, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. https://doi.org/10.1126/scisignal.2004088
Gao J, Lindsay J, Watt S et al (2016) Abstract 5277: The cBioPortal for cancer genomics and its application in precision oncology. Can Res 76:5277–5277. https://doi.org/10.1158/1538-7445.Am2016-5277
doi: 10.1158/1538-7445.Am2016-5277
Gaspar D, Veiga AS, Castanho MA (2013) From antimicrobial to anticancer peptides A Review. Front Microbiol 4:294. https://doi.org/10.3389/fmicb.2013.00294
doi: 10.3389/fmicb.2013.00294
pubmed: 24101917
pmcid: 3787199
Gaulton A, Bellis LJ, Bento AP et al (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40:D1100-1107. https://doi.org/10.1093/nar/gkr777
doi: 10.1093/nar/gkr777
pubmed: 21948594
Gay S, Binz PA, Hochstrasser DF et al (2002) Peptide mass fingerprinting peak intensity prediction: extracting knowledge from spectra. Proteomics 2:1374–1391. https://doi.org/10.1002/1615-9861(200210)2:10%3c1374::AID-PROT1374%3e3.0.CO;2-D
doi: 10.1002/1615-9861(200210)2:10<1374::AID-PROT1374>3.0.CO;2-D
pubmed: 12422355
Ghandi M, Huang FW, Jane-Valbuena J et al (2019) Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503–508. https://doi.org/10.1038/s41586-019-1186-3
doi: 10.1038/s41586-019-1186-3
pubmed: 31068700
pmcid: 6697103
Ghimire A, Tayara H, Xuan Z, et al. (2022) CSatDTA: Prediction of Drug-Target Binding Affinity Using Convolution Model with Self-Attention. Int J Mol Sci 23. https://doi.org/10.3390/ijms23158453
Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32:1267–1284. https://doi.org/10.1101/gad.314617.118
doi: 10.1101/gad.314617.118
pubmed: 30275043
pmcid: 6169832
Gutman DA, Cobb J, Somanna D et al (2013) Cancer Digital Slide Archive: an informatics resource to support integrated in silico analysis of TCGA pathology data. J Am Med Inform Assoc 20:1091–1098. https://doi.org/10.1136/amiajnl-2012-001469
doi: 10.1136/amiajnl-2012-001469
pubmed: 23893318
pmcid: 3822112
Han L, Guo X, Du R et al (2022) Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases. J Ovarian Res 15:75. https://doi.org/10.1186/s13048-022-01003-2
doi: 10.1186/s13048-022-01003-2
pubmed: 35739532
pmcid: 9219195
Hasan MR, Alsaiari AA, Fakhurji BZ, et al. (2022) Application of Mathematical Modeling and Computational Tools in the Modern Drug Design and Development Process. Molecules 27. https://doi.org/10.3390/molecules27134169
He X, Liu X, Zuo F et al (2023) Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Semin Cancer Biol 88:187–200. https://doi.org/10.1016/j.semcancer.2022.12.009
doi: 10.1016/j.semcancer.2022.12.009
pubmed: 36596352
Heath AP, Ferretti V, Agrawal S et al (2021) The NCI Genomic Data Commons. Nat Genet 53:257–262. https://doi.org/10.1038/s41588-021-00791-5
doi: 10.1038/s41588-021-00791-5
pubmed: 33619384
Hewett M, Oliver DE, Rubin DL et al (2002) PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res 30:163–165. https://doi.org/10.1093/nar/30.1.163
doi: 10.1093/nar/30.1.163
pubmed: 11752281
pmcid: 99138
Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727–730. https://doi.org/10.1038/nrd892
doi: 10.1038/nrd892
pubmed: 12209152
Horai H, Arita M, Kanaya S et al (2010) MassBank: a public repository for sharing mass spectral data for life sciences. J Mass Spectrom 45:703–714. https://doi.org/10.1002/jms.1777
doi: 10.1002/jms.1777
pubmed: 20623627
Horejs C-M (2023) Artificial intelligence identifies new cancer biomarkers. Nature Reviews Bioengineering:1–1
Hu Z, Yuan J, Long M et al (2021) The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer 2:1406–1422. https://doi.org/10.1038/s43018-021-00282-w
doi: 10.1038/s43018-021-00282-w
pubmed: 35121907
pmcid: 9940627
Intlekofer AM, Finley LWS (2019) Metabolic signatures of cancer cells and stem cells. Nat Metab 1:177–188. https://doi.org/10.1038/s42255-019-0032-0
doi: 10.1038/s42255-019-0032-0
pubmed: 31245788
pmcid: 6594714
International Agency for Research on Cancer. https://gco.iarc.fr/today . Cited 17 December 2023
Irwin JJ, Shoichet BK (2005) ZINC–a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177–182. https://doi.org/10.1021/ci049714+
doi: 10.1021/ci049714+
pubmed: 15667143
pmcid: 1360656
Isberg V, Mordalski S, Munk C et al (2016) GPCRdb: an information system for G protein-coupled receptors. Nucleic Acids Res 44:D356-364. https://doi.org/10.1093/nar/gkv1178
doi: 10.1093/nar/gkv1178
pubmed: 26582914
Jassal B, Matthews L, Viteri G et al (2020) The reactome pathway knowledgebase. Nucleic Acids Res 48:D498–D503. https://doi.org/10.1093/nar/gkz1031
doi: 10.1093/nar/gkz1031
pubmed: 31691815
Jensen F (2017) Introduction to computational chemistry. John wiley & sons
Jeon J, Nim S, Teyra J et al (2014) A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. Genome Med 6:57. https://doi.org/10.1186/s13073-014-0057-7
doi: 10.1186/s13073-014-0057-7
pubmed: 25165489
pmcid: 4143549
Jespersen MC, Peters B, Nielsen M et al (2017) BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res 45:W24–W29. https://doi.org/10.1093/nar/gkx346
doi: 10.1093/nar/gkx346
pubmed: 28472356
pmcid: 5570230
Jia L, Sun Y (2011) SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets 11:347–356. https://doi.org/10.2174/156800911794519734
doi: 10.2174/156800911794519734
pubmed: 21247385
pmcid: 3323109
Jiang J, Yuan J, Hu Z et al (2022) Systematic illumination of druggable genes in cancer genomes. Cell Rep 38:110400. https://doi.org/10.1016/j.celrep.2022.110400
doi: 10.1016/j.celrep.2022.110400
pubmed: 35196490
pmcid: 8919705
Jiang Q, Wang Y, Hao Y et al (2009) miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 37:D98-104. https://doi.org/10.1093/nar/gkn714
doi: 10.1093/nar/gkn714
pubmed: 18927107
Jin I, Nam H (2021) HiDRA: Hierarchical Network for Drug Response Prediction with Attention. J Chem Inf Model 61:3858–3867. https://doi.org/10.1021/acs.jcim.1c00706
doi: 10.1021/acs.jcim.1c00706
pubmed: 34342985
Jochems C, Schlom J (2011) Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236:567–579. https://doi.org/10.1258/ebm.2011.011007
doi: 10.1258/ebm.2011.011007
pubmed: 21486861
Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265. https://doi.org/10.1038/nrc1317
doi: 10.1038/nrc1317
pubmed: 15057285
Jumper J, Evans R, Pritzel A et al (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596:583–589. https://doi.org/10.1038/s41586-021-03819-2
doi: 10.1038/s41586-021-03819-2
pubmed: 34265844
pmcid: 8371605
Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30. https://doi.org/10.1093/nar/28.1.27
doi: 10.1093/nar/28.1.27
pubmed: 10592173
pmcid: 102409
Katz JE, Dumlao DS, Clarke S et al (2004) A new technique (COMSPARI) to facilitate the identification of minor compounds in complex mixtures by GC/MS and LC/MS: tools for the visualization of matched datasets. J Am Soc Mass Spectrom 15:580–584. https://doi.org/10.1016/j.jasms.2003.12.011
doi: 10.1016/j.jasms.2003.12.011
pubmed: 15047062
Kim K-W, Roh JK, Wee H-J et al (2016a) Cancer Drug Discovery. Springer
doi: 10.1007/978-94-024-0844-7
Kim P, Cheng F, Zhao J et al (2016b) ccmGDB: a database for cancer cell metabolism genes. Nucleic Acids Res 44:D959-968. https://doi.org/10.1093/nar/gkv1128
doi: 10.1093/nar/gkv1128
pubmed: 26519468
Kim S, Thiessen PA, Bolton EE et al (2016c) PubChem Substance and Compound databases. Nucleic Acids Res 44:D1202-1213. https://doi.org/10.1093/nar/gkv951
doi: 10.1093/nar/gkv951
pubmed: 26400175
Kinase Profiling Inhibitor Database. https://www.kinase-screen.mrc.ac.uk/kinase-inhibitors . Cited July 2023
Ko CY, Chu TH, Hsu CC et al (2022) Bioinformatics Analyses Identify the Therapeutic Potential of ST8SIA6 for Colon Cancer. J Pers Med 12:401. https://doi.org/10.3390/jpm12030401
doi: 10.3390/jpm12030401
pubmed: 35330401
pmcid: 8953768
Koscielny G, An P, Carvalho-Silva D et al (2017) Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res 45:D985–D994. https://doi.org/10.1093/nar/gkw1055
doi: 10.1093/nar/gkw1055
pubmed: 27899665
Kuenzi BM, Park J, Fong SH et al (2020) Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells. Cancer Cell 38(672–684):e676. https://doi.org/10.1016/j.ccell.2020.09.014
doi: 10.1016/j.ccell.2020.09.014
Kuhlmann L, Cummins E, Samudio I et al (2018) Cell-surface proteomics for the identification of novel therapeutic targets in cancer. Expert Rev Proteomics 15:259–275. https://doi.org/10.1080/14789450.2018.1429924
doi: 10.1080/14789450.2018.1429924
pubmed: 29343144
Kuhn M, von Mering C, Campillos M et al (2008) STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 36:D684-688. https://doi.org/10.1093/nar/gkm795
doi: 10.1093/nar/gkm795
pubmed: 18084021
Kumar A, Misra BB (2019) Challenges and Opportunities in Cancer Metabolomics. Proteomics 19:e1900042. https://doi.org/10.1002/pmic.201900042
doi: 10.1002/pmic.201900042
pubmed: 30950571
Kumar B, Singh S, Skvortsova I et al (2017) Promising Targets in Anti-cancer Drug Development: Recent Updates. Curr Med Chem 24:4729–4752. https://doi.org/10.2174/0929867324666170331123648
doi: 10.2174/0929867324666170331123648
pubmed: 28393696
Kumar R, Chaudhary K, Gupta S et al (2013) CancerDR: cancer drug resistance database. Sci Rep 3:1445. https://doi.org/10.1038/srep01445
doi: 10.1038/srep01445
pubmed: 23486013
pmcid: 3595698
Kutmon M, van Iersel MP, Bohler A et al (2015) PathVisio 3: an extendable pathway analysis toolbox. PLoS Comput Biol 11:e1004085. https://doi.org/10.1371/journal.pcbi.1004085
doi: 10.1371/journal.pcbi.1004085
pubmed: 25706687
pmcid: 4338111
Kwon YW, Jo HS, Bae S et al (2021) Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery. Front Med (Lausanne) 8:747333. https://doi.org/10.3389/fmed.2021.747333
doi: 10.3389/fmed.2021.747333
pubmed: 34631760
Lamb J, Crawford ED, Peck D et al (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935. https://doi.org/10.1126/science.1132939
doi: 10.1126/science.1132939
pubmed: 17008526
Lauschke VM, Milani L, Ingelman-Sundberg M (2017) Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments. AAPS J 20:4. https://doi.org/10.1208/s12248-017-0161-x
doi: 10.1208/s12248-017-0161-x
pubmed: 29181807
Lee YT, Tan YJ, Oon CE (2018) Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol 834:188–196. https://doi.org/10.1016/j.ejphar.2018.07.034
doi: 10.1016/j.ejphar.2018.07.034
pubmed: 30031797
Leloup L, Wells A (2011) Calpains as potential anti-cancer targets. Expert Opin Ther Targets 15:309–323. https://doi.org/10.1517/14728222.2011.553611
doi: 10.1517/14728222.2011.553611
pubmed: 21244345
pmcid: 3076675
Lesk AM (2017) Introduction to genomics. Oxford University Press
doi: 10.1093/hesc/9780198754831.001.0001
Leth-Larsen R, Lund RR, Ditzel HJ (2010) Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics 9:1369–1382. https://doi.org/10.1074/mcp.R900006-MCP200
doi: 10.1074/mcp.R900006-MCP200
pubmed: 20382631
pmcid: 2938092
Li B, Meng YQ, Li Z et al (2019) MiR-629-3p-induced downregulation of SFTPC promotes cell proliferation and predicts poor survival in lung adenocarcinoma. Artif Cells Nanomed Biotechnol 47:3286–3296. https://doi.org/10.1080/21691401.2019.1648283
doi: 10.1080/21691401.2019.1648283
pubmed: 31379200
Li C, Tian C, Zeng Y et al (2022) Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3–4 NSCLC patients. BMC Med Genomics 15:33. https://doi.org/10.1186/s12920-022-01184-1
doi: 10.1186/s12920-022-01184-1
pubmed: 35193578
pmcid: 8862473
Li J, Duncan DT, Zhang B (2010) CanProVar: a human cancer proteome variation database. Hum Mutat 31:219–228. https://doi.org/10.1002/humu.21176
doi: 10.1002/humu.21176
pubmed: 20052754
pmcid: 2829365
Li J, Lu Y, Akbani R et al (2013) TCPA: a resource for cancer functional proteomics data. Nat Methods 10:1046–1047. https://doi.org/10.1038/nmeth.2650
doi: 10.1038/nmeth.2650
pubmed: 24037243
pmcid: 4076789
Li J, Zhang S, Liu T et al (2020a) Neural inductive matrix completion with graph convolutional networks for miRNA-disease association prediction. Bioinformatics 36:2538–2546. https://doi.org/10.1093/bioinformatics/btz965
doi: 10.1093/bioinformatics/btz965
pubmed: 31904845
Li K, Guo ZW, Zhai XM, et al. (2020) RBPTD: a database of cancer-related RNA-binding proteins in humans. Database (Oxford) 2020. https://doi.org/10.1093/database/baz156
Li M, Wang Y, Zheng R et al (2021) DeepDSC: A Deep Learning Method to Predict Drug Sensitivity of Cancer Cell Lines. IEEE/ACM Trans Comput Biol Bioinf 18:575–582. https://doi.org/10.1109/TCBB.2019.2919581
doi: 10.1109/TCBB.2019.2919581
Li Q, Xu W (2005) Novel anticancer targets and drug discovery in post genomic age. Curr Med Chem Anticancer Agents 5:53–63. https://doi.org/10.2174/1568011053352631
doi: 10.2174/1568011053352631
pubmed: 15720261
Li Y, Li L (2019) Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis. J Ovarian Res 12:106. https://doi.org/10.1186/s13048-019-0580-7
doi: 10.1186/s13048-019-0580-7
pubmed: 31703725
pmcid: 6839211
Li Y, Ma D, Chen D et al (2023) ACP-GBDT: An improved anticancer peptide identification method with gradient boosting decision tree. Front Genet 14:1165765. https://doi.org/10.3389/fgene.2023.1165765
doi: 10.3389/fgene.2023.1165765
pubmed: 37065496
pmcid: 10090421
Liu Q, Wang HG (2012) Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Commun Integr Biol 5:557–565. https://doi.org/10.4161/cib.21554
doi: 10.4161/cib.21554
pubmed: 23336025
pmcid: 3541322
Liu Y, Hu B, Fu C et al (2010) DCDB: drug combination database. Bioinformatics 26:587–588. https://doi.org/10.1093/bioinformatics/btp697
doi: 10.1093/bioinformatics/btp697
pubmed: 20031966
Liu Y, Zeng X, He Z et al (2017) Inferring microRNA-disease associations by random walk on a heterogeneous network with multiple data sources. IEEE/ACM Trans Comput Biol Bioinf 14:905–915. https://doi.org/10.1109/TCBB.2016.2550432
doi: 10.1109/TCBB.2016.2550432
Liu Z, Liu J, Liu X et al (2022) CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response. Nucleic Acids Res 50:D1184–D1199. https://doi.org/10.1093/nar/gkab860
doi: 10.1093/nar/gkab860
pubmed: 34570230
Lloyd JP, Soellner MB, Merajver SD et al (2021) Impact of between-tissue differences on pan-cancer predictions of drug sensitivity. PLoS Comput Biol 17:e1008720. https://doi.org/10.1371/journal.pcbi.1008720
doi: 10.1371/journal.pcbi.1008720
pubmed: 33630864
pmcid: 7906305
Lu M, Qiu S, Jiang X et al (2021) Development and Validation of Epigenetic Modification-Related Signals for the Diagnosis and Prognosis of Hepatocellular Carcinoma. Front Oncol 11:649093. https://doi.org/10.3389/fonc.2021.649093
doi: 10.3389/fonc.2021.649093
pubmed: 34235075
pmcid: 8256693
Lu M, Xu L, Jian X et al. (2022) dbPepNeo2.0: A Database for Human Tumor Neoantigen Peptides From Mass Spectrometry and TCR Recognition. Front Immunol 13:855976. https://doi.org/10.3389/fimmu.2022.855976
Luna A, Elloumi F, Varma S et al (2021) Cell Miner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics. Nucleic Acids Res 49:D1083–D1093. https://doi.org/10.1093/nar/gkaa968
doi: 10.1093/nar/gkaa968
pubmed: 33196823
Luo H, Wang J, Li M et al (2016) Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm. Bioinformatics 32:2664–2671. https://doi.org/10.1093/bioinformatics/btw228
doi: 10.1093/bioinformatics/btw228
pubmed: 27153662
Lv C, Wu X, Wang X et al (2017) The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: a general template for research on TCMs. Sci Rep 7:352. https://doi.org/10.1038/s41598-017-00535-8
doi: 10.1038/s41598-017-00535-8
pubmed: 28336967
pmcid: 5428649
Madej T, Addess KJ, Fong JH et al (2012) MMDB: 3D structures and macromolecular interactions. Nucleic Acids Res 40:D461-464. https://doi.org/10.1093/nar/gkr1162
doi: 10.1093/nar/gkr1162
pubmed: 22135289
Mader JS, Hoskin DW (2006) Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 15:933–946. https://doi.org/10.1517/13543784.15.8.933
doi: 10.1517/13543784.15.8.933
pubmed: 16859395
Mauri C, Bosma A (2012) Immune regulatory function of B cells. Annu Rev Immunol 30:221–241. https://doi.org/10.1146/annurev-immunol-020711-074934
doi: 10.1146/annurev-immunol-020711-074934
pubmed: 22224776
Mei H, Gu Q, Wang W et al (2022) CRISPR-surfaceome: An online tool for designing highly efficient sgRNAs targeting cell surface proteins. Comput Struct Biotechnol J 20:3833–3838. https://doi.org/10.1016/j.csbj.2022.07.026
doi: 10.1016/j.csbj.2022.07.026
pubmed: 35891797
pmcid: 9307495
Melge AR, Manzoor K, Nair SV et al. (2019) In Silico Modeling of FDA-Approved Drugs for Discovery of Anti-Cancer Agents: A Drug-Repurposing ApproachIn Silico Drug Design. Elsevier, 577–608
Meneur C, Eswaran S, Adiga D et al (2021) Analysis of Nuclear Encoded Mitochondrial Gene Networks in Cervical Cancer. Asian Pac J Cancer Prev 22:1799–1811. https://doi.org/10.31557/APJCP.2021.22.6.1799
doi: 10.31557/APJCP.2021.22.6.1799
pubmed: 34181336
pmcid: 8418845
Menyhart O, Gyorffy B (2021) Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J 19:949–960. https://doi.org/10.1016/j.csbj.2021.01.009
doi: 10.1016/j.csbj.2021.01.009
pubmed: 33613862
pmcid: 7868685
Mesri M (2014) Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. Adv Med 2014:238045. https://doi.org/10.1155/2014/238045
doi: 10.1155/2014/238045
pubmed: 26556407
pmcid: 4590950
Milne GW, Nicklaus MC, Driscoll JS et al (1994) National Cancer Institute Drug Information System 3D database. J Chem Inf Comput Sci 34:1219–1224. https://doi.org/10.1021/ci00021a032
doi: 10.1021/ci00021a032
pubmed: 7962217
Missailidis S (2008) Anticancer therapeutics. John Wiley & Sons
doi: 10.1002/9780470697047
Mitsopoulos C, Di Micco P, Fernandez EV et al (2021) canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Res 49:D1074–D1082. https://doi.org/10.1093/nar/gkaa1059
doi: 10.1093/nar/gkaa1059
pubmed: 33219674
Mohammed M, Mwambi H, Mboya IB et al (2021) A stacking ensemble deep learning approach to cancer type classification based on TCGA data. Sci Rep 11:15626. https://doi.org/10.1038/s41598-021-95128-x
doi: 10.1038/s41598-021-95128-x
pubmed: 34341396
pmcid: 8329290
Monga M, Sausville EA (2002) Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia 16:520–526. https://doi.org/10.1038/sj.leu.2402464
doi: 10.1038/sj.leu.2402464
pubmed: 11960328
Morganti S, Tarantino P, Ferraro E et al (2019) Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Adv Exp Med Biol 1168:9–30. https://doi.org/10.1007/978-3-030-24100-1_2
doi: 10.1007/978-3-030-24100-1_2
pubmed: 31713162
Mottini C, Napolitano F, Li Z et al (2021) Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets. Semin Cancer Biol 68:59–74. https://doi.org/10.1016/j.semcancer.2019.09.023
doi: 10.1016/j.semcancer.2019.09.023
pubmed: 31562957
Musa A, Ghoraie LS, Zhang SD et al (2018) A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform 19:506–523. https://doi.org/10.1093/bib/bbw112
doi: 10.1093/bib/bbw112
pubmed: 28069634
Nam NH, Parang K (2003) Current targets for anticancer drug discovery. Curr Drug Targets 4:159–179. https://doi.org/10.2174/1389450033346966
doi: 10.2174/1389450033346966
pubmed: 12558068
Nantasenamat C, Prachayasittikul V (2015) Maximizing computational tools for successful drug discovery. Expert Opin Drug Discov 10:321–329. https://doi.org/10.1517/17460441.2015.1016497
doi: 10.1517/17460441.2015.1016497
pubmed: 25693813
Nawy T (2018) A pan-cancer atlas. Nat Methods 15:407. https://doi.org/10.1038/s41592-018-0020-4
doi: 10.1038/s41592-018-0020-4
pubmed: 29855579
Paananen J, Fortino V (2020) An omics perspective on drug target discovery platforms. Brief Bioinform 21:1937–1953. https://doi.org/10.1093/bib/bbz122
doi: 10.1093/bib/bbz122
pubmed: 31774113
Pandiyan S, Wang L (2022) A comprehensive review on recent approaches for cancer drug discovery associated with artificial intelligence. Comput Biol Med 150:106140. https://doi.org/10.1016/j.compbiomed.2022.106140
doi: 10.1016/j.compbiomed.2022.106140
pubmed: 36179510
Pang Z, Chong J, Zhou G et al (2021) MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res 49:W388–W396. https://doi.org/10.1093/nar/gkab382
doi: 10.1093/nar/gkab382
pubmed: 34019663
pmcid: 8265181
Pantziarka P, Capistrano IR, De Potter A et al (2021) An Open Access Database of Licensed Cancer Drugs. Front Pharmacol 12:627574. https://doi.org/10.3389/fphar.2021.627574
doi: 10.3389/fphar.2021.627574
pubmed: 33776770
pmcid: 7991999
Park HW, Pitti T, Madhavan T et al (2022a) MLACP 2.0: An updated machine learning tool for anticancer peptide prediction. Comput Struct Biotechnol J 20:4473–4480
doi: 10.1016/j.csbj.2022.07.043
Park SJ, Chang SJ, Suh DH et al (2022b) A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer. BMC Cancer 22:28. https://doi.org/10.1186/s12885-021-09138-z
doi: 10.1186/s12885-021-09138-z
pubmed: 34980026
pmcid: 8722005
Pence HE, Williams A (2010) ChemSpider: An Online Chemical Information Resource. J Chem Educ 87:1123–1124. https://doi.org/10.1021/ed100697w
doi: 10.1021/ed100697w
Poorebrahim M, Abazari MF, Moradi L et al (2022) Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors. PLoS Comput Biol 18:e1009962. https://doi.org/10.1371/journal.pcbi.1009962
doi: 10.1371/journal.pcbi.1009962
pubmed: 35472201
pmcid: 9041843
Prada-Gracia D, Huerta-Yepez S, Moreno-Vargas LM (2016) Application of computational methods for anticancer drug discovery, design, and optimization. Bol Med Hosp Infant Mex 73:411–423. https://doi.org/10.1016/j.bmhimx.2016.10.006
doi: 10.1016/j.bmhimx.2016.10.006
pubmed: 29421286
pmcid: 7110968
Preto AJ, Matos-Filipe P, Mourao J, et al. (2022) SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning. Gigascience 11. https://doi.org/10.1093/gigascience/giac087
Pu L, Singha M, Ramanujam J et al (2022) CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling. Oncotarget 13:695–706. https://doi.org/10.18632/oncotarget.28234
doi: 10.18632/oncotarget.28234
pubmed: 35601606
pmcid: 9119687
Quintero M, Adamoski D, Reis LMD et al (2017) Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. BMC Cancer 17:727. https://doi.org/10.1186/s12885-017-3726-2
doi: 10.1186/s12885-017-3726-2
pubmed: 29115931
pmcid: 5688804
Radoux CJ, Vianello F, McGreig J et al (2022) The druggable genome: Twenty years later. Front Bioinform 2:958378. https://doi.org/10.3389/fbinf.2022.958378
doi: 10.3389/fbinf.2022.958378
pubmed: 36304325
pmcid: 9580872
Rafique R, Islam SMR, Kazi JU (2021) Machine learning in the prediction of cancer therapy. Comput Struct Biotechnol J 19:4003–4017. https://doi.org/10.1016/j.csbj.2021.07.003
doi: 10.1016/j.csbj.2021.07.003
pubmed: 34377366
pmcid: 8321893
Rahman MM, Islam MR, Rahman F et al (2022) Emerging Promise of Computational Techniques in Anti-Cancer Research: At a Glance. Bioengineering (Basel) 9:335. https://doi.org/10.3390/bioengineering9080335
doi: 10.3390/bioengineering9080335
pubmed: 35892749
Rajapakse VN, Luna A, Yamade M et al. (2018) CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. iScience 10:247–264. https://doi.org/10.1016/j.isci.2018.11.029
Ren F, Ding X, Zheng M et al (2023) AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor. Chem Sci 14:1443–1452. https://doi.org/10.1039/d2sc05709c
doi: 10.1039/d2sc05709c
pubmed: 36794205
pmcid: 9906638
Repana D, Nulsen J, Dressler L et al (2019) The Network of Cancer Genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens. Genome Biol 20:1. https://doi.org/10.1186/s13059-018-1612-0
doi: 10.1186/s13059-018-1612-0
pubmed: 30606230
pmcid: 6317252
Rezaei N, SpringerLink (2021) Cancer immunology : bench to bedside immunotherapy of cancers. Springer Nature Cham, Switzerland
Rho SB, Kim BR, Kang S (2011) A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3’-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol 120:121–127. https://doi.org/10.1016/j.ygyno.2010.10.003
doi: 10.1016/j.ygyno.2010.10.003
pubmed: 21035837
Richards V (1980) Cancer immunology--an overviewProg Exp Tumor Res. pp. 1–60
Rodriguez-Antona C, Taron M (2015) Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med 277:201–217. https://doi.org/10.1111/joim.12321
doi: 10.1111/joim.12321
pubmed: 25338550
Romero PR, Kobayashi N, Wedell JR et al (2020) BioMagResBank (BMRB) as a Resource for Structural Biology. Methods Mol Biol 2112:187–218. https://doi.org/10.1007/978-1-0716-0270-6_14
doi: 10.1007/978-1-0716-0270-6_14
pubmed: 32006287
pmcid: 8064287
Rosenbluth JM, Mays DJ, Pino MF et al (2008) A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 28:5951–5964. https://doi.org/10.1128/MCB.00305-08
doi: 10.1128/MCB.00305-08
pubmed: 18678646
pmcid: 2547001
Rothfels K, Milacic M, Matthews L et al (2023) Using the Reactome Database Curr Protoc 3:e722. https://doi.org/10.1002/cpz1.722
doi: 10.1002/cpz1.722
pubmed: 37053306
Rudnick PA, Markey SP, Roth J et al (2016) A Description of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Common Data Analysis Pipeline. J Proteome Res 15:1023–1032. https://doi.org/10.1021/acs.jproteome.5b01091
doi: 10.1021/acs.jproteome.5b01091
pubmed: 26860878
pmcid: 5117628
Saei AA, Beusch CM, Chernobrovkin A et al (2019) ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery. Nat Commun 10:5715. https://doi.org/10.1038/s41467-019-13582-8
doi: 10.1038/s41467-019-13582-8
pubmed: 31844049
pmcid: 6915695
Sager M, Yeat NC, Pajaro-Van der Stadt S et al (2015) Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization. Expert Rev Mol Diagn 15:1589–1603. https://doi.org/10.1586/14737159.2015.1105133
doi: 10.1586/14737159.2015.1105133
pubmed: 26565429
Sarver AL, Sarver AE, Yuan C et al (2018) OMCD: OncomiR Cancer Database. BMC Cancer 18:1223. https://doi.org/10.1186/s12885-018-5085-z
doi: 10.1186/s12885-018-5085-z
pubmed: 30522456
pmcid: 6282392
Sathyanarayanan A, Gupta R, Thompson EW et al (2020) A comparative study of multi-omics integration tools for cancer driver gene identification and tumour subtyping. Brief Bioinform 21:1920–1936. https://doi.org/10.1093/bib/bbz121
doi: 10.1093/bib/bbz121
pubmed: 31774481
Schlitzer A, Sivakamasundari V, Chen J et al (2015) Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nat Immunol 16:718–728. https://doi.org/10.1038/ni.3200
doi: 10.1038/ni.3200
pubmed: 26054720
Schwartsmann G, Ratain MJ, Cragg GM et al (2002) Anticancer drug discovery and development throughout the world. J Clin Oncol 20:47S-59S. https://doi.org/10.1200/JCO.2002.07.122
doi: 10.1200/JCO.2002.07.122
pubmed: 12235225
Seashore-Ludlow B, Rees MG, Cheah JH et al (2015) Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov 5:1210–1223. https://doi.org/10.1158/2159-8290.CD-15-0235
doi: 10.1158/2159-8290.CD-15-0235
pubmed: 26482930
pmcid: 4631646
Shankavaram UT, Varma S, Kane D et al (2009) Cell Miner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 10:277. https://doi.org/10.1186/1471-2164-10-277
doi: 10.1186/1471-2164-10-277
pubmed: 19549304
pmcid: 2709662
Shannon P, Markiel A, Ozier O et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498–2504. https://doi.org/10.1101/gr.1239303
doi: 10.1101/gr.1239303
pubmed: 14597658
pmcid: 403769
Sharma A, Lysenko A, Boroevich KA et al (2023) DeepInsight-3D architecture for anti-cancer drug response prediction with deep-learning on multi-omics. Sci Rep 13:2483. https://doi.org/10.1038/s41598-023-29644-3
doi: 10.1038/s41598-023-29644-3
pubmed: 36774402
pmcid: 9922304
Sharma P, Wagner K, Wolchok JD et al (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11:805–812. https://doi.org/10.1038/nrc3153
doi: 10.1038/nrc3153
pubmed: 22020206
pmcid: 3426440
Sharma V, Singh A, Chauhan S et al (2024) Role of Artificial Intelligence in Drug Discovery and Target Identification in Cancer. Curr Drug Deliv 21:870–886. https://doi.org/10.2174/1567201821666230905090621
doi: 10.2174/1567201821666230905090621
pubmed: 37670704
Shimada K, Bachman JA, Muhlich JL, et al. (2021) shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data. Elife 10. https://doi.org/10.7554/eLife.57116
Shin J, Piao Y, Bang D, et al. (2022) DRPreter: Interpretable Anticancer Drug Response Prediction Using Knowledge-Guided Graph Neural Networks and Transformer. Int J Mol Sci 23. https://doi.org/10.3390/ijms232213919
Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823. https://doi.org/10.1038/nrc1951
doi: 10.1038/nrc1951
pubmed: 16990858
Shukla N, Somwar R, Smith RS et al (2016) Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. Cancer Res 76:4525–4534. https://doi.org/10.1158/0008-5472.CAN-16-1040
doi: 10.1158/0008-5472.CAN-16-1040
pubmed: 27256563
pmcid: 5484002
Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763
doi: 10.3322/caac.21763
pubmed: 36633525
Smirnov P, Kofia V, Maru A et al (2018) PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies. Nucleic Acids Res 46:D994–D1002. https://doi.org/10.1093/nar/gkx911
doi: 10.1093/nar/gkx911
pubmed: 30053271
Sondka Z, Bamford S, Cole CG et al (2018) The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer 18:696–705. https://doi.org/10.1038/s41568-018-0060-1
doi: 10.1038/s41568-018-0060-1
pubmed: 30293088
pmcid: 6450507
Srinivas PR, Verma M, Zhao Y et al (2002) Proteomics for cancer biomarker discovery. Clin Chem 48:1160–1169. https://doi.org/10.1093/clinchem/48.8.1160
doi: 10.1093/clinchem/48.8.1160
pubmed: 12142368
Stephens NA, Gallagher IJ, Rooyackers O et al (2010) Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med 2:1. https://doi.org/10.1186/gm122
doi: 10.1186/gm122
pubmed: 20193046
pmcid: 2829926
Su R, Liu X, Wei L et al (2019) Deep-Resp-Forest: A deep forest model to predict anti-cancer drug response. Methods 166:91–102. https://doi.org/10.1016/j.ymeth.2019.02.009
doi: 10.1016/j.ymeth.2019.02.009
pubmed: 30772464
Sun J, Patel CB, Jang T et al (2020) High levels of ubidecarenone (oxidized CoQ(10)) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells. Sci Rep 10:13899. https://doi.org/10.1038/s41598-020-70969-0
doi: 10.1038/s41598-020-70969-0
pubmed: 32807842
pmcid: 7431533
Sun M, Hu H, Pang W, et al. (2023) ACP-BC: A Model for Accurate Identification of Anticancer Peptides Based on Fusion Features of Bidirectional Long Short-Term Memory and Chemically Derived Information. Int J Mol Sci 24. https://doi.org/10.3390/ijms242015447
Sun M, Yang S, Hu X, et al. (2022) ACPNet: A Deep Learning Network to Identify Anticancer Peptides by Hybrid Sequence Information. Molecules 27. https://doi.org/10.3390/molecules27051544
Supplitt S, Karpinski P, Sasiadek M, et al. (2021) Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine. Int J Mol Sci 22. https://doi.org/10.3390/ijms22031422
Suri GS, Kaur G, Carbone GM et al (2023) Metabolomics in Oncology. Cancer Rep (Hoboken) 6:e1795. https://doi.org/10.1002/cnr2.1795
doi: 10.1002/cnr2.1795
pubmed: 36811317
Sussman JL, Lin D, Jiang J et al (1998) Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules. Acta Crystallogr D Biol Crystallogr 54:1078–1084. https://doi.org/10.1107/s0907444998009378
doi: 10.1107/s0907444998009378
pubmed: 10089483
Tan HT, Lee YH, Chung MC (2012) Cancer proteomics. Mass Spectrom Rev 31:583–605. https://doi.org/10.1002/mas.20356
doi: 10.1002/mas.20356
pubmed: 22422534
Tan X, Li D, Huang P, et al. (2020) dbPepNeo: a manually curated database for human tumor neoantigen peptides. Database (Oxford) 2020. https://doi.org/10.1093/database/baaa004
Tang G, Cho M, Wang X (2022) OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer. Nucleic Acids Res 50:D1334–D1339. https://doi.org/10.1093/nar/gkab970
doi: 10.1093/nar/gkab970
pubmed: 34718715
Tate JG, Bamford S, Jubb HC et al (2019) COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res 47:D941–D947. https://doi.org/10.1093/nar/gky1015
doi: 10.1093/nar/gky1015
pubmed: 30371878
Thi Phan L, Woo Park H, Pitti T et al (2022) MLACP 2.0: An updated machine learning tool for anticancer peptide prediction. Comput Struct Biotechnol J 20:4473–4480. https://doi.org/10.1016/j.csbj.2022.07.043
doi: 10.1016/j.csbj.2022.07.043
pubmed: 36051870
pmcid: 9421197
Thorvaldsdottir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14:178–192. https://doi.org/10.1093/bib/bbs017
doi: 10.1093/bib/bbs017
pubmed: 22517427
Tian J, Cai Y, Li Y et al (2021) CancerImmunityQTL: a database to systematically evaluate the impact of genetic variants on immune infiltration in human cancer. Nucleic Acids Res 49:D1065–D1073. https://doi.org/10.1093/nar/gkaa805
doi: 10.1093/nar/gkaa805
pubmed: 33010176
Tian J, Wang Z, Mei S et al (2019) CancerSplicingQTL: a database for genome-wide identification of splicing QTLs in human cancer. Nucleic Acids Res 47:D909–D916. https://doi.org/10.1093/nar/gky954
doi: 10.1093/nar/gky954
pubmed: 30329095
Tomczak K, Czerwinska P, Wiznerowicz M (2015) The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 19:A68-77. https://doi.org/10.5114/wo.2014.47136
doi: 10.5114/wo.2014.47136
pubmed: 25691825
Tran B, Dancey JE, Kamel-Reid S et al (2012) Cancer genomics: technology, discovery, and translation. J Clin Oncol 30:647–660. https://doi.org/10.1200/JCO.2011.39.2316
doi: 10.1200/JCO.2011.39.2316
pubmed: 22271477
Tsherniak A, Vazquez F, Montgomery PG et al (2017) Defining a Cancer Dependency Map. Cell 170(564–576):e516. https://doi.org/10.1016/j.cell.2017.06.010
doi: 10.1016/j.cell.2017.06.010
Tsimberidou AM, Fountzilas E, Bleris L et al (2022) Transcriptomics and solid tumors: The next frontier in precision cancer medicine. Semin Cancer Biol 84:50–59. https://doi.org/10.1016/j.semcancer.2020.09.007
doi: 10.1016/j.semcancer.2020.09.007
pubmed: 32950605
Tyagi A, Tuknait A, Anand P et al (2015) CancerPPD: a database of anticancer peptides and proteins. Nucleic Acids Res 43:D837-843. https://doi.org/10.1093/nar/gku892
doi: 10.1093/nar/gku892
pubmed: 25270878
Ursu O, Holmes J, Knockel J et al (2017) DrugCentral: online drug compendium. Nucleic Acids Res 45:D932–D939. https://doi.org/10.1093/nar/gkw993
doi: 10.1093/nar/gkw993
pubmed: 27789690
Vandiedonck C (2018) Genetic association of molecular traits: A help to identify causative variants in complex diseases. Clin Genet 93:520–532. https://doi.org/10.1111/cge.13187
doi: 10.1111/cge.13187
pubmed: 29194587
Varadi M, Anyango S, Deshpande M et al (2022) AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res 50:D439–D444. https://doi.org/10.1093/nar/gkab1061
doi: 10.1093/nar/gkab1061
pubmed: 34791371
Vasaikar SV, Straub P, Wang J et al (2018) LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 46:D956–D963. https://doi.org/10.1093/nar/gkx1090
doi: 10.1093/nar/gkx1090
pubmed: 29136207
Vitorino R, Guedes S, Trindade F et al (2020) De novo sequencing of proteins by mass spectrometry. Expert Rev Proteomics 17:595–607. https://doi.org/10.1080/14789450.2020.1831387
doi: 10.1080/14789450.2020.1831387
pubmed: 33016158
Vladimer G, Alt I, Sehlke R, et al. (2022) 23P Enriching for response: Patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material. Immuno-Oncol Technol 16. https://doi.org/10.1016/j.iotech.2022.100128
Waas M, Snarrenberg ST, Littrell J et al (2020) SurfaceGenie: a web-based application for prioritizing cell-type-specific marker candidates. Bioinformatics 36:3447–3456. https://doi.org/10.1093/bioinformatics/btaa092
doi: 10.1093/bioinformatics/btaa092
pubmed: 32053146
pmcid: 7267825
Wang G, Wang F, Meng Z et al (2022) Uncovering potential genes in colorectal cancer based on integrated and DNA methylation analysis in the gene expression omnibus database. BMC Cancer 22:138. https://doi.org/10.1186/s12885-022-09185-0
doi: 10.1186/s12885-022-09185-0
pubmed: 35114976
pmcid: 8815138
Wang G, Ye Y, Yang X et al (2011) Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS ONE 6:e14573. https://doi.org/10.1371/journal.pone.0014573
doi: 10.1371/journal.pone.0014573
pubmed: 21283735
pmcid: 3024967
Wang L, Song Y, Wang H et al (2023) Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade. Pharmaceuticals (Basel) 16:253. https://doi.org/10.3390/ph16020253
doi: 10.3390/ph16020253
pubmed: 37259400
Wang Y, Yang Y, Chen S, et al. (2021) DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration. Brief Bioinform 22. https://doi.org/10.1093/bib/bbab048
Weber BL (2002) Cancer genomics. Cancer Cell 1:37–47. https://doi.org/10.1016/s1535-6108(02)00026-0
doi: 10.1016/s1535-6108(02)00026-0
pubmed: 12086886
Wei L, Zhou C, Chen H et al (2018) ACPred-FL: a sequence-based predictor using effective feature representation to improve the prediction of anti-cancer peptides. Bioinformatics 34:4007–4016. https://doi.org/10.1093/bioinformatics/bty451
doi: 10.1093/bioinformatics/bty451
pubmed: 29868903
pmcid: 6247924
Welling DB, Collier KA, Burns SS et al (2021) Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol 6:1008–1019. https://doi.org/10.1002/lio2.643
doi: 10.1002/lio2.643
pubmed: 34667843
pmcid: 8513424
Wishart DS, Guo A, Oler E et al (2022) HMDB 5.0: the Human Metabolome Database for 2022. Nucleic Acids Res 50:D622–D631. https://doi.org/10.1093/nar/gkab1062
doi: 10.1093/nar/gkab1062
pubmed: 34986597
Wishart DS, Knox C, Guo AC et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668-672. https://doi.org/10.1093/nar/gkj067
doi: 10.1093/nar/gkj067
pubmed: 16381955
Wittmann-Liebold B, Graack HR, Pohl T (2006) Two-dimensional gel electrophoresis as tool for proteomics studies in combination with protein identification by mass spectrometry. Proteomics 6:4688–4703. https://doi.org/10.1002/pmic.200500874
doi: 10.1002/pmic.200500874
pubmed: 16933336
Workman P, Antolin AA, Al-Lazikani B (2019) Transforming cancer drug discovery with Big Data and AI. Expert Opin Drug Discov 14:1089–1095. https://doi.org/10.1080/17460441.2019.1637414
doi: 10.1080/17460441.2019.1637414
pubmed: 31284790
Wu J, Xiao Y, Lin M et al (2023) DeepCancerMap: A versatile deep learning platform for target- and cell-based anticancer drug discovery. Eur J Med Chem 255:115401. https://doi.org/10.1016/j.ejmech.2023.115401
doi: 10.1016/j.ejmech.2023.115401
pubmed: 37116265
Wu Q, Zhang B, Sun Y et al (2019) Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis. Onco Targets Ther 12:3545–3563. https://doi.org/10.2147/OTT.S198621
doi: 10.2147/OTT.S198621
pubmed: 31190860
pmcid: 6526173
Wu X, Zeng W, Lin F et al (2022) Anticancer Peptide Prediction via Multi-Kernel CNN and Attention Model. Front Genet 13:887894. https://doi.org/10.3389/fgene.2022.887894
doi: 10.3389/fgene.2022.887894
pubmed: 35571059
pmcid: 9092594
Wulfkuhle JD, Liotta LA, Petricoin EF (2003) Proteomic applications for the early detection of cancer. Nat Rev Cancer 3:267–275. https://doi.org/10.1038/nrc1043
doi: 10.1038/nrc1043
pubmed: 12671665
Xie B, Ding Q, Han H et al (2013) miRCancer: a microRNA-cancer association database constructed by text mining on literature. Bioinformatics 29:638–644. https://doi.org/10.1093/bioinformatics/btt014
doi: 10.1093/bioinformatics/btt014
pubmed: 23325619
Yadav D, Tanveer A, Malviya N et al (2018) Overview and Principles of Bioengineering. In: Barh D, Azevedo V (eds) Omics Technologies and Bio-Engineering. Academic Press, pp 3–23
doi: 10.1016/B978-0-12-804659-3.00001-4
Yan D, Zheng G, Wang C et al (2022) HIT 2.0: an enhanced platform for Herbal Ingredients’ Targets. Nucleic Acids Res 50:D1238–D1243. https://doi.org/10.1093/nar/gkab1011
doi: 10.1093/nar/gkab1011
pubmed: 34986599
Yang C, Liu Y, Lv C et al (2024) CanCellVar: A database for single-cell variants map in human cancer. Am J Hum Genet 111:1420–1430. https://doi.org/10.1016/j.ajhg.2024.05.014
doi: 10.1016/j.ajhg.2024.05.014
pubmed: 38838674
pmcid: 11267512
Yang PM, Chou CJ, Tseng SH et al (2017) Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. Oncotarget 8:46145–46162. https://doi.org/10.18632/oncotarget.17574
doi: 10.18632/oncotarget.17574
pubmed: 28526810
pmcid: 5542256
Yang W, Soares J, Greninger P et al (2013) Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41:D955-961. https://doi.org/10.1093/nar/gks1111
doi: 10.1093/nar/gks1111
pubmed: 23180760
Yang Z, Ren F, Liu C et al (2010) dbDEMC: a database of differentially expressed miRNAs in human cancers. BMC Genomics 11(Suppl 4):S5. https://doi.org/10.1186/1471-2164-11-S4-S5
doi: 10.1186/1471-2164-11-S4-S5
pubmed: 21143814
pmcid: 3005935
Ye H, Zhang X, Chen Y et al (2016) Ranking novel cancer driving synthetic lethal gene pairs using TCGA data. Oncotarget 7:55352–55367. https://doi.org/10.18632/oncotarget.10536
doi: 10.18632/oncotarget.10536
pubmed: 27438146
pmcid: 5342422
Ye X, Kaczmarczyk JA, Luke B et al. (2020) Cell surface protein enrichment for biomarker and drug target discovery using mass spectrometry-based proteomics. In: Haleem JI, Timothy DV (eds) Proteomic and Metabolomic Approaches to Biomarker Discovery. Academic Press Boston, pp. 409–420
Yi HC, You ZH, Zhou X et al (2019) ACP-DL: A Deep Learning Long Short-Term Memory Model to Predict Anticancer Peptides Using High-Efficiency Feature Representation. Mol Ther Nucleic Acids 17:1–9. https://doi.org/10.1016/j.omtn.2019.04.025
doi: 10.1016/j.omtn.2019.04.025
pubmed: 31173946
pmcid: 6554234
Yingtaweesittikul H, Wu J, Mongia A et al (2023) CREAMMIST: an integrative probabilistic database for cancer drug response prediction. Nucleic Acids Res 51:D1242–D1248. https://doi.org/10.1093/nar/gkac911
doi: 10.1093/nar/gkac911
pubmed: 36259664
You Y, Lai X, Pan Y et al (2022) Artificial intelligence in cancer target identification and drug discovery. Signal Transduct Target Ther 7:156. https://doi.org/10.1038/s41392-022-00994-0
doi: 10.1038/s41392-022-00994-0
pubmed: 35538061
pmcid: 9090746
Yu L, Jing R, Liu F et al (2020) DeepACP: A Novel Computational Approach for Accurate Identification of Anticancer Peptides by Deep Learning Algorithm. Mol Ther Nucleic Acids 22:862–870. https://doi.org/10.1016/j.omtn.2020.10.005
doi: 10.1016/j.omtn.2020.10.005
pubmed: 33230481
pmcid: 7658571
Zhang C, Kim SH (2003) Overview of structural genomics: from structure to function. Curr Opin Chem Biol 7:28–32. https://doi.org/10.1016/s1367-5931(02)00015-7
doi: 10.1016/s1367-5931(02)00015-7
pubmed: 12547423
Zhang GL, DeLuca DS, Brusic V (2011a) Database resources for proteomics-based analysis of cancer. Methods Mol Biol 723:349–364. https://doi.org/10.1007/978-1-61779-043-0_22
doi: 10.1007/978-1-61779-043-0_22
pubmed: 21370076
Zhang J, Baran J, Cros A et al (2011) International Cancer Genome Consortium Data Portal–a one-stop shop for cancer genomics data. Database (Oxford) 2011:bar026. https://doi.org/10.1093/database/bar026
doi: 10.1093/database/bar026
pubmed: 21930502
Zhang J, Finney RP, Rowe W et al (2007) Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). Genome Res 17:1111–1117. https://doi.org/10.1101/gr.5963407
doi: 10.1101/gr.5963407
pubmed: 17525135
pmcid: 1899122
Zhang Y, Chen F, Chandrashekar DS et al (2022) Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nat Commun 13:2669. https://doi.org/10.1038/s41467-022-30342-3
doi: 10.1038/s41467-022-30342-3
pubmed: 35562349
pmcid: 9106650
Zhang Y, Yao Y, Chen P et al. (2020) Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy. J Immunother Cancer 8. https://doi.org/10.1136/jitc-2020-001247
Zhang Z, Lu M, Qin Y et al (2021) Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front Immunol 12:672356. https://doi.org/10.3389/fimmu.2021.672356
doi: 10.3389/fimmu.2021.672356
pubmed: 33936118
pmcid: 8085349
Zhao Y, Chen X, Chen J et al. (2023) Decoding Connectivity Map-based drug repurposing for oncotherapy. Brief Bioinform 24. https://doi.org/10.1093/bib/bbad142
Zhavoronkov A (2018) Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry. Mol Pharm 15:4311–4313. https://doi.org/10.1021/acs.molpharmaceut.8b00930
doi: 10.1021/acs.molpharmaceut.8b00930
pubmed: 30269508
Zheng B, Fang L (2022) Spatially resolved transcriptomics provide a new method for cancer research. J Exp Clin Cancer Res 41:179. https://doi.org/10.1186/s13046-022-02385-3
doi: 10.1186/s13046-022-02385-3
pubmed: 35590346
pmcid: 9118771
Zhou JB, Tang D, He L et al (2023) Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation. Pharmacol Res 194:106830. https://doi.org/10.1016/j.phrs.2023.106830
doi: 10.1016/j.phrs.2023.106830
pubmed: 37343647
Zhou L, Wu Y, Xin L et al (2020) Development of RNA binding proteins expression signature for prognosis prediction in gastric cancer patients. Am J Transl Res 12:6775–6792
pubmed: 33194072
pmcid: 7653620
Zhu Y, Zhou Y, Jiang H et al (2021) Analysis of core genes for colorectal cancer prognosis based on immune and stromal scores. PeerJ 9:e12452. https://doi.org/10.7717/peerj.12452
doi: 10.7717/peerj.12452
pubmed: 34820188
pmcid: 8607933
Zhu Z, Zhang F, Hu H et al (2016) Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet 48:481–487. https://doi.org/10.1038/ng.3538
doi: 10.1038/ng.3538
pubmed: 27019110
Zuo Z, Wang P, Chen X et al (2021) SWnet: a deep learning model for drug response prediction from cancer genomic signatures and compound chemical structures. BMC Bioinformatics 22:434. https://doi.org/10.1186/s12859-021-04352-9
doi: 10.1186/s12859-021-04352-9
pubmed: 34507532
pmcid: 8434731